行情

EYES

EYES

Second Sight Med
NASDAQ

实时行情|Nasdaq Last Sale

4.190
-0.410
-8.91%
已收盘, 16:00 01/22 EST
开盘
4.560
昨收
4.600
最高
4.690
最低
4.190
成交量
6.69万
成交额
--
52周最高
9.60
52周最低
4.190
市值
6,526.30万
市盈率(TTM)
-0.1869
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EYES 新闻

  • Can Second Sight Medical Products (NASDAQ:EYES) Afford To Invest In Growth?
  • Simply Wall St..01/14 12:43
  • The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results
  • Benzinga.01/08 13:12
  • The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
  • Benzinga.01/07 12:57
  • Second Sight (-9%) reverse splits shares 1:8
  • seekingalpha.01/06 21:39

更多

所属板块

医疗设备、用品及经销
+0.94%
医疗设备和用品
+0.76%

热门股票

名称
价格
涨跌幅

EYES 简况

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
展开

Webull提供Second Sight Medical Products Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。